ADC Therapeutics Voluntarily Pauses Enrollment In Phase 2 LOTIS-9 Trial Of Zynlonta (Loncastuximab Tesirine-lpyl) And Rituximab (Lonca-r) In Unfit Or Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics has voluntarily paused enrollment in its Phase 2 LOTIS-9 trial of Zynlonta (Loncastuximab Tesirine-lpyl) and Rituximab (Lonca-r) in unfit or frail patients with previously untreated Diffuse Large B-Cell Lymphoma.
July 11, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ADC Therapeutics' decision to pause enrollment in its Phase 2 LOTIS-9 trial could potentially delay the development and approval of Zynlonta and Rituximab, which may negatively impact the company's stock in the short term.
The pause in enrollment for the Phase 2 LOTIS-9 trial could potentially delay the development and approval of Zynlonta and Rituximab. This could lead to a delay in potential revenue from these drugs, which could negatively impact ADC Therapeutics' stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100